Skip to main content

Kymera Therapeutics

Kymera Therapeutics Inc is an American clinical-stage biopharmaceutical company focused on targeted protein degradation for immunology, inflammation, and oncology indications. The company utilizes its proprietary Pegasus technology platform to design small molecule degrader medicines that selectively remove disease-causing proteins. Principal revenue is derived from strategic research collaborations, licensing agreements, and milestone payments from global biopharmaceutical partners. Core end markets embrace immunology medical practices, oncology clinics, and specialized clinical research institutions globally. Kymera Therapeutics holds a pioneer position in the biopharmaceutical industry for targeted protein degradation drug candidate development. The company is headquartered in Watertown, Massachusetts, and its common stock trades on the Nasdaq Global Select Market.

8 of the funds FundTelligence covers report a position in Kymera Therapeutics.

Legal name
Kymera Therapeutics Inc
Sector
Health Care
Country
United States
Funds holding it
8

Funds holding Kymera Therapeutics

Loading...